<DOC>
	<DOCNO>NCT01228357</DOCNO>
	<brief_summary>The purpose study determine whether genetic information associate individual depressive symptom .</brief_summary>
	<brief_title>Predict Antidepressant Responsiveness Using Pharmacogenomics</brief_title>
	<detailed_description>The primary hypothesis variation candidate gene associate individual symptom patient depression . The Second hypothesis patient associate genetic variation suffer longer associate symptom patient without associate genetic variation .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<criteria>Eligible patient enrol clinical trial program hte Samsung Medical Center Geropsychiatry Affective Disorder Clinics ( Seoul , Korea ) . They receive semistructured diagnostic interview , Samsung Psychiatric Evaluation Schedule . The affective disorder section Samsung Psychiatric Evaluation Schedule use Korean version structure clinical interview diagnostic statistical manual mental disorder , Fourth edition . interview one patient 's family member objective diagnosis final diagnosis decision agreement two psychiatric physician receive psychotropic medication within 2 week study fluoxetine within 4 week potential study participant pregnancy , significant medical condition , abnormal laboratory baseline value , unstable psychiatric feature ( eg.suicidal ) , history alcohol drug dependence , seizure , head trauma loss consciousness , neurological illness , concomitant Axis I psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pharmacogenomics</keyword>
	<keyword>Depressed Patients</keyword>
</DOC>